Änderungen von Dokument Pustulosis subcornealis Sneddon-Wilkinson
Zuletzt geändert von Thomas Brinkmeier am 2025/04/25 20:40
<
>
bearbeitet von Thomas Brinkmeier
am 2021/06/02 22:04
am 2021/06/02 22:04
bearbeitet von Thomas Brinkmeier
am 2019/02/02 21:13
am 2019/02/02 21:13
Änderungskommentar:
Es gibt keinen Kommentar für diese Version
Zusammenfassung
Details
- Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.Dermatologie_Kompendium - Größe
-
... ... @@ -1,1 +1,0 @@ 1 -620.9 KB - Inhalt
- Wikiderm.EntryClass[0]
-
- Eintrag
-
... ... @@ -65,45 +65,9 @@ 65 65 (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV 66 66 67 67 (% class="Eintrag-2" %) 68 -(% class="Feature" %)DD:(%%) (% class=" Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)68 +(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa 69 69 70 -(% class="Ebene-1" %) 71 -(% class="Bullet" %)-(%%) Dermatitis herpetiformis 72 - 73 -(% class="Ebene-1" %) 74 -(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji 75 - 76 -(% class="Ebene-1" %) 77 -(% class="Bullet" %)-(%%) Impetigo contagiosa 78 - 79 -(% class="Ebene-1" %) 80 -(% class="Bullet" %)-(%%) Pemphigus foliaceus 81 - 82 82 (% class="Eintrag-2" %) 83 - 84 - 85 -(% class="Ebene-1" %) 86 -(% class="Bullet" %)-(%%) Psoriasis pustulosa 87 - 88 -(% class="Ebene-1" %) 89 -(% class="Bullet" %)-(%%) Tinea incognito 90 - 91 -(% class="Ebene-2" %) 92 -(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]] 93 - 94 -(% class="Eintrag-2" %) 95 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}} 96 - 97 -(% class="Ebene-1" %) 98 -(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]] 99 - 100 -(% class="Ebene-1" %) 101 -(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]] 102 - 103 -(% class="Ebene-1" %) 104 -(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]] 105 - 106 -(% class="Eintrag-2" %) 107 107 (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal 108 108 109 109 (% class="Ebene-2" %) ... ... @@ -127,12 +127,6 @@ 127 127 (% class="Ebene-5" %) 128 128 (% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%) 129 129 130 -(% class="Ebene-2" %) 131 -(% class="Bullet" %)-(%%) Dapson Gel 132 - 133 -(% class="Ebene-3" %) 134 -(% class="Feature" %)Lit:(%%) J Dermatol. 2019 Jun 24. [[http:~~/~~/doi.org/10.1111/1346-8138.14953>>url:http://doi.org/10.1111/1346-8138.14953]] 135 - 136 136 (% class="Ebene-1" %) 137 137 (% class="Bullet" %)-(%%) systemisch 138 138 ... ... @@ -176,12 +176,6 @@ 176 176 (% class="Feature" %)Lit:(%%) Dermatol Ther. 2019 Jan 14:e12818. [[http:~~/~~/doi.org/10.1111/dth.12818>>url:http://doi.org/10.1111/dth.12818]] 177 177 178 178 (% class="Ebene-2" %) 179 -(% class="Bullet" %)-(%%) Apremilast 180 - 181 -(% class="Ebene-3" %) 182 -(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]] 183 - 184 -(% class="Ebene-2" %) 185 185 (% class="Bullet" %)-(%%) Anti-TNF-alpha 186 186 187 187 (% class="Ebene-3" %) ... ... @@ -203,10 +203,4 @@ 203 203 (% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich) 204 204 205 205 (% class="Ebene-5" %) 206 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%) 207 - 208 -(% class="Ebene-2" %) 209 -(% class="Bullet" %)-(%%) Guselkumab 210 - 211 -(% class="Ebene-3" %) 212 -(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]] 158 +(% class="Feature" %)PT:(%%) CR